Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone.

This article focuses on the management of kratom use disorder through telehealth-facilitated, unobserved home induction of buprenorphine-naloxone, a medication approved for opioid use disorder treatment. It presents two case studies of patients consuming 35 grams of kratom daily who successfully underwent home induction via telehealth without adverse effects, though they stabilized on different maintenance doses. The report highlights that, despite the absence of formal treatment guidelines for kratom use disorder, buprenorphine-naloxone induction at home may be a feasible alternative to traditional clinic-based induction, especially where access is limited. It also suggests that factors beyond daily kratom dose, such as duration of use and individual psychological factors, may influence optimal buprenorphine-naloxone dosing. The article underscores the need for increased awareness among healthcare providers and the public about kratom's potential for dependence.